现代中枢神经系统放疗对多发性硬化复发与进展的影响
该回顾性队列纳入2005年1月至2024年8月接受中枢神经系统放疗、剂量大于5 Gy的33例多发性硬化患者,中位随访20个月。放疗后无临床复发或新发多发性硬化进展,但7/33例出现新的T2或钆增强T1病灶。
要点
- 现代中枢神经系统放疗后未见多发性硬化临床复发或新发进展。
- 7/33例出现新的T2或钆增强T1病灶,多数位于照射野外。
- 出现新病灶者均未使用高效多发性硬化治疗药物。
核心结论
- 现代中枢神经系统电离辐射在多发硬化患者中未伴随临床恶化,但可能伴随无症状性炎症性多发性硬化疾病活动风险增加。
研究设计与样本
- 回顾性病历审查,纳入2005年1月至2024年8月接受中枢神经系统放疗的多发性硬化患者33例。
- 纳入标准:确诊多发性硬化、脑或脊髓实质接受大于5 Gy治疗性放疗、放疗后有临床神经科与脑MRI随访。
主要发现
- 放疗时中位年龄60岁(IQR 54–68),中位随访20个月(范围3–99)。
- 放疗部位:15/33(45%)针对中枢神经系统,5例(15%)邻近中枢神经系统实质,13例(39%)在中枢神经系统外但中枢神经系统受照大于5 Gy。
- 放疗时多发性硬化病程:复发缓解型19/33、继发进展型11/33、原发进展型3/33,13例(39%)在接受疾病修饰治疗。
- 放疗后无临床复发或新发多发性硬化进展;7/33例出现新的T2或钆增强T1病灶,7例患者共10个新脱髓鞘病灶中6/10位于照射野外。
- 7例患者末次随访EDSS较放疗前增加≥1分(中位1.5,范围1–7),其中5例残疾增加被认为继发于放疗指征(3例胶质母细胞瘤、2例脑膜瘤)。
临床怎么用
- 对合并多发性硬化的中枢神经系统肿瘤患者,现代放疗未观察到临床复发或进展,但需关注影像学上无症状炎症活动。
- 放疗后随访应包含脑MRI以监测新发T2或钆增强病灶。
- 出现新病灶的患者均未使用高效疾病修饰治疗,提示需多学科评估疾病修饰治疗状态。
局限性
- 回顾性单中心设计,样本量33例,随访时间范围宽(3–99个月)。
- 无法排除放疗指征本身(如胶质母细胞瘤、脑膜瘤)对EDSS变化的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Central nervous system (CNS) radiation is associated with primary demyelination and neurotoxicity in patients with existing demyelinating disorders. We examined the safety of modern ionizing-radiation techniques in multiple-sclerosis (MS) patients. PATIENTS AND METHODS: Patients with MS undergoing CNS radiation for any reason between January 2005, and August 2024 were identified by chart review. Inclusion criteria were: 1) confirmed diagnosis of MS; 2) Receiving therapeutic radiation with a dose of greater than 5 Gray (Gy) to brain or spinal cord parenchyma; 3) Clinical neurology and brain MRI follow-up available following radiation. RESULTS: Thirty-three patients were included. Median age at radiation was 60 years (54--68 IQR) and median follow-up, 20 months (range 3-99). Radiation focused on the CNS in 15/33 (45%), 5 (15%) targeted locations adjacent to the CNS parenchyma (meningioma 4, trigeminal neuralgia 1), and 13 (39%), outside the CNS with > 5 Gy delivered to the CNS. Clinical MS course at radiation was relapsing remitting (19/33), secondary progressive (11/33), and primary progressive (3/33). Thirteen patients (39%) were on MS disease-modifying therapy. No clinical relapse or new-onset MS progression followed radiation. New T2 or gadolinium-enhancing lesions on T1 MRI occurred in 7/33. Radiation-field data were analysed with reference to location of 10 new demyelinating lesions in 7 patients. Most lesions lay outside the irradiated area (6/10). No patients with new lesions were on high-efficacy medications. Seven patients experienced increased expanded disability status scale (EDSS) pre-radiation to last follow-up by ≥ 1 point (median 1.5, range 1-7). One patient had known progressive disease while 5 patients' increased disability was thought secondary to their radiation indication (3 glioblastoma and 2 meningioma). CONCLUSIONS: Modern-day ionizing radiation to the CNS in patients with multiple sclerosis was not associated with clinical worsening but can potentially be associated with an increased risk of asymptomatic inflammatory MS disease activity.
引用
- Zhao-Fleming HH, Ebner DK, Sperduto W, et al. Impact of modern central nervous system radiation on multiple sclerosis relapse and progression. Clin Transl Radiat Oncol. 2026. PMID: 42088775. doi:10.1016/j.ctro.2026.101176
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。